Stirling DI - Search Results

1

Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production.

Muller GW, Chen R, Huang SY, Corral LG, Wong LM, Patterson RT, Chen Y, Kaplan G, Stirling DI. Muller GW, et al. Among authors: stirling di. Bioorg Med Chem Lett. 1999 Jun 7;9(11):1625-30. doi: 10.1016/s0960-894x(99)00250-4. Bioorg Med Chem Lett. 1999. PMID: 10386948

2

Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor.

Man HW, Schafer P, Wong LM, Patterson RT, Corral LG, Raymon H, Blease K, Leisten J, Shirley MA, Tang Y, Babusis DM, Chen R, Stirling D, Muller GW. Man HW, et al. J Med Chem. 2009 Mar 26;52(6):1522-4. doi: 10.1021/jm900210d. J Med Chem. 2009. PMID: 19256507

3

Alpha-fluoro-substituted thalidomide analogues.

Man HW, Corral LG, Stirling DI, Muller GW. Man HW, et al. Among authors: stirling di. Bioorg Med Chem Lett. 2003 Oct 20;13(20):3415-7. doi: 10.1016/s0960-894x(03)00778-9. Bioorg Med Chem Lett. 2003. PMID: 14505639

4

Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity.

Corral LG, Muller GW, Moreira AL, Chen Y, Wu M, Stirling D, Kaplan G. Corral LG, et al. Mol Med. 1996 Jul;2(4):506-15. Mol Med. 1996. PMID: 8827720 Free PMC article.

5

Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity.

Muller GW, Corral LG, Shire MG, Wang H, Moreira A, Kaplan G, Stirling DI. Muller GW, et al. Among authors: stirling di. J Med Chem. 1996 Aug 16;39(17):3238-40. doi: 10.1021/jm9603328. J Med Chem. 1996. PMID: 8765505 No abstract available.

6

Thalidomide analogs and PDE4 inhibition.

Muller GW, Shire MG, Wong LM, Corral LG, Patterson RT, Chen Y, Stirling DI. Muller GW, et al. Among authors: stirling di. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2669-74. doi: 10.1016/s0960-894x(98)00475-2. Bioorg Med Chem Lett. 1998. PMID: 9873600

7

Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha.

Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, Patterson RT, Stirling DI, Kaplan G. Corral LG, et al. Among authors: stirling di. J Immunol. 1999 Jul 1;163(1):380-6. J Immunol. 1999. PMID: 10384139

8

Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner.

Payvandi F, Wu L, Haley M, Schafer PH, Zhang LH, Chen RS, Muller GW, Stirling DI. Payvandi F, et al. Among authors: stirling di. Cell Immunol. 2004 Aug;230(2):81-8. doi: 10.1016/j.cellimm.2004.09.003. Cell Immunol. 2004. PMID: 15598423

9

Immunomodulatory drugs (IMiDs) increase the production of IL-2 from stimulated T cells by increasing PKC-theta activation and enhancing the DNA-binding activity of AP-1 but not NF-kappaB, OCT-1, or NF-AT.

Payvandi F, Wu L, Naziruddin SD, Haley M, Parton A, Schafer PH, Chen RS, Muller GW, Hughes CC, Stirling DI. Payvandi F, et al. Among authors: stirling di. J Interferon Cytokine Res. 2005 Oct;25(10):604-16. doi: 10.1089/jir.2005.25.604. J Interferon Cytokine Res. 2005. PMID: 16241859

10

The synthetic compound CC-5079 is a potent inhibitor of tubulin polymerization and tumor necrosis factor-alpha production with antitumor activity.

Zhang LH, Wu L, Raymon HK, Chen RS, Corral L, Shirley MA, Narla RK, Gamez J, Muller GW, Stirling DI, Bartlett JB, Schafer PH, Payvandi F. Zhang LH, et al. Among authors: stirling di. Cancer Res. 2006 Jan 15;66(2):951-9. doi: 10.1158/0008-5472.CAN-05-2083. Cancer Res. 2006. PMID: 16424030

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

85 results

Search Page